Immunohistochemical Differentiation of High-grade Prostate Carcinoma From Urothelial Carcinoma

  title={Immunohistochemical Differentiation of High-grade Prostate Carcinoma From Urothelial Carcinoma},
  author={Ai-Ying Chuang and Angelo M. DeMarzo and Robert Veltri and Rajni B. Sharma and Charles J. Bieberich and Jonathan I. Epstein},
  journal={The American Journal of Surgical Pathology},
The histologic distinction between high-grade prostate cancer and infiltrating high-grade urothelial cancer may be difficult, and has significant implications because each disease may be treated very differently (ie, hormone therapy for prostate cancer and chemotherapy for urothelial cancer). Immunohistochemistry of novel and established prostatic and urothelial markers using tissue microarrays (TMAs) were studied. Prostatic markers studied included: prostate-specific antigen (PSA), prostein… 

Differential Immunohistochemical Profiles for Distinguishing Prostate Carcinoma and Urothelial Carcinoma

Prostatic and urothelial markers, including PSA, NKX3.1, p63, thrombomodulin, and GATA3 are very useful for differentiating PAC from UC pathologically.

Diagnostic utility of androgen receptor expression in discriminating poorly differentiated urothelial and prostate carcinoma

An institutional review of all cases from 2006 to 2012 in which AR IHC had been performed concluded that AR is an important marker as it is best able to distinguish between poorly differentiated urothelial and prostate carcinoma.

Comparison of Immunohistochemistry Expression of CK7, HMWK and PSA in High-Grade Prostatic Adenocarcinoma and Bladder Transitional Cell Carcinoma

A panel of immunohistochemical stains can be used to differentiate high-grade prostate adenocarcinoma from urothelial bladder carcinoma in those cases which are challenging to diagnose.

Potential Utiliy of GATA3 and P63 Immunohistochemistry in Differentiating Urothelial Carcinoma from Prostate Adenocarcinoma

GATA3 and p63 IHC are sensitive markers for UC and can be used to distinguish prostatic adenocarcinomas from urothelial carcinomas in difficult cases and are also highly specific in excluding high-grade prostatic carcinoma.

Immunohistochemical detection of prostate-specific antigen expression in primary urothelial carcinoma of the urinary bladder.

Focal expression of PSA can occasionally be detected in some large, invasive urothelial cancer cells and this phenotypic change should be considered in the differential diagnosis of poorly differentiated carcinoma of the lower urinary tract.

Immunohistochemical Expression of Prostatic Antigens in Adenocarcinoma and Villous Adenoma of the Urinary Bladder

The surprising finding that a subset of invasive and in situ adenocarcinomas of the bladder demonstrated immunoreactivity for P501S and PSMA should warrant caution when using these markers in differentiating prostatic from bladder adenOCarcinoma.

Integrated immunohistochemical and molecular analysis improves diagnosis of high-grade carcinoma in the urinary bladder of patients with prior radiation therapy for prostate cancer

The findings highlight the importance of considering prostatic origin in high-grade carcinoma of the urinary bladder of patients with a history of treated prostate cancer, even when the immunohistochemical findings favor urothelial carcinoma.


A diagnosis of cancer in urogenital area should not exclude the existence of other concomitant malignancy, especially in patients in the sixth decade of age, as shown by the case of a smoker male patient, 63-year-old.

The utility of PSMA and PSA immunohistochemistry in the cytologic diagnosis of metastatic prostate carcinoma

Results indicate that PSMA is a highly sensitive and specific immunomarker for the detection of metastatic prostate carcinoma in cytology specimens.

Utility of GATA3 Immunohistochemistry in Differentiating Urothelial Carcinoma From Prostate Adenocarcinoma and Squamous Cell Carcinomas of the Uterine Cervix, Anus, and Lung

GATA3 is a sensitive marker for UC, and positive staining in UC is typically nonfocal and moderate or strong in intensity, whereas some cervical and anal SCCs can be GATA3 positive, unlike in UC, staining is more commonly focal and weak.



Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores.

  • N. Goldstein
  • Medicine
    American journal of clinical pathology
  • 2002
The prostate can be the primary site of metastatic adenocarcinoma that is nonreactive for PAP and PSA and has CK7 or CK20 reactivity in fewer than 50% of the cells.

Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature

A morphological differential diagnosis based selection of immunohistochemical markers is highlighted as a novel approach in the diagnosis of prostate cancer in routine surgical pathology practice.

Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia.

It is concluded that PSMA overexpression is detected in high-grade PIN and is associated with a higher Gleason score of prostate cancer.

Potential Utility of Uroplakin III, Thrombomodulin, High Molecular Weight Cytokeratin, and Cytokeratin 20 in Noninvasive, Invasive, and Metastatic Urothelial (Transitional Cell) Carcinomas

A role for an antibody panel that includes UROIII, THR, HMWCK, and CK20 in the diagnosis of urothelial tumors is indicated and the co expression of two of three non-UROIII markers (THR, HMTK, CK20) suggests uroclinical origin but requires clinicopathologic correlation.

Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma.

An optimal immunohistochemical panel to distinguish poorly differentiated prostate (PCa) from urothelial (UCa) carcinoma was selected from a panel consisting of prostate-specific antigen (PSA) and

Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer

[−5/−7]pPSA (native proPSA) may be a better marker than PSA and PAP in characterizing metastatic prostate adenocarcinoma, with most of the cases showing positivity for the marker.